journal
https://read.qxmd.com/read/38766861/implementation-of-obesity-science-into-clinical-practice-a-scientific-statement-from-the-american-heart-association
#1
REVIEW
Deepika Laddu, Ian J Neeland, Mercedes Carnethon, Fatima C Stanford, Morgana Mongraw-Chaffin, Bethany Barone Gibbs, Chiadi E Ndumele, Chris T Longenecker, Misook L Chung, Goutham Rao
Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Over the past decade, obesity science has evolved to improve knowledge of its multifactorial causes, identifying important biological causes and sociological determinants of obesity. Treatments for obesity have also continued to develop, with more evidence-based programs for lifestyle modification, new pharmacotherapies, and robust data to support bariatric surgery...
May 20, 2024: Circulation
https://read.qxmd.com/read/38753452/early-versus-late-initiation-of-direct-oral-anticoagulants-after-ischemic-stroke-in-people-with-atrial-fibrillation-and-hemorrhagic-transformation-prespecified-subanalysis-of-the-randomized-controlled-elan-trial
#2
JOURNAL ARTICLE
Roman Rohner, Markus Kneihsl, Martina B Goeldlin, Arsany Hakim, Mattia Branca, Stefanie Abend, Waldo Valenzuela Pinilla, Sabine Fenzl, Beata Rezny-Kasprzak, Daniel Strbian, Sven Trelle, Maurizio Paciaroni, Götz Thomalla, Patrik Michel, Krassen Nedeltchev, Thomas Gattringer, Else C Sandset, Leo Bonati, Diana Aguiar de Sousa, P N Sylaja, George Ntaios, Masatoshi Koga, Zuzana Gdovinova, Robin Lemmens, Natan M Bornstein, Peter Kelly, Mira Katan, Thomas Horvath, Jesse Dawson, Urs Fischer
BACKGROUND: Whether hemorrhagic transformation (HT) modifies the treatment effect of early versus late initiation of direct oral anticoagulation (DOAC) in people with ischemic stroke and atrial fibrillation is unknown. METHODS: This is a post-hoc analysis of the ELAN trial. The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage (sICH), major extracranial bleeding, systemic embolism, or vascular death within 30 days...
May 16, 2024: Circulation
https://read.qxmd.com/read/38752370/genome-wide-crispr-screen-identifies-an-nf2-adherens-junction-mechanistic-dependency-for-cardiac-lineage
#3
JOURNAL ARTICLE
Chang Jie Mick Lee, Matias I Autio, Wen Hao Zheng, Yoohyun Song, Shyi Chyi Wang, Darren Chen Pei Wong, Jingwei Xiao, Yike Zhu, Permeen Yusoff, Xi Yei, Wan Kee Chock, Boon Chuan Low, Marius Sudol, Roger S-Y Foo
BACKGROUND: Cardiomyocyte differentiation involves a stepwise clearance of repressors and fate-restricting regulators through the modulation of BMP (bone morphogenic protein)/Wnt-signaling pathways. However, the mechanisms and how regulatory roadblocks are removed with specific developmental signaling pathways remain unclear. METHODS: We conducted a genome-wide CRISPR screen to uncover essential regulators of cardiomyocyte specification in human embryonic stem cells using a myosin heavy chain 6 ( MYH6 )-GFP (green fluorescence protein) reporter system...
May 16, 2024: Circulation
https://read.qxmd.com/read/38752352/randomized-multicenter-study-to-assess-the-effects-of-different-doses-of-sildenafil-on-mortality-in-adults-with-pulmonary-arterial-hypertension
#4
JOURNAL ARTICLE
Marius M Hoeper, Ralf Ewert, Pavel Jansa, Yuriy Sirenko, Andris Skride, Cecile Balagtas, Sarah Hackley, Susanne Vogt, Paula Abreu, Scott Haughie, Tarek Hassan, Ronald J Oudiz
BACKGROUND: Sildenafil, approved for pulmonary arterial hypertension (PAH), has a recommended adult dose of 20 mg TID, with a previously approved 5-mg TID dose by the US Food and Drug Administration. Safety concerns arose because of common off-label use of higher doses, particularly after pediatric data linked higher doses to increased mortality. To assess this, the Food and Drug Administration mandated a study evaluating the effects of various sildenafil doses on mortality in adults with PAH...
May 16, 2024: Circulation
https://read.qxmd.com/read/38752340/allele-specific-suppression-of-variant-mhc-with-high-precision-rna-nuclease-crispr-cas13d-prevents-hypertrophic-cardiomyopathy
#5
JOURNAL ARTICLE
Ping Yang, Yingmei Lou, Zilong Geng, Zhizhao Guo, Shuo Wu, Yige Li, Kaiyuan Song, Ting Shi, Shasha Zhang, Junhao Xiong, Alex F Chen, Dali Li, William T Pu, Lintai Da, Yan Zhang, Kun Sun, Bing Zhang
BACKGROUND: Familial hypertrophic cardiomyopathy has severe clinical complications of heart failure, arrhythmia, and sudden cardiac death. Heterozygous single nucleotide variants (SNVs) of sarcomere genes such as MYH7 are the leading cause of this type of disease. CRISPR-Cas13 (clustered regularly interspaced short palindromic repeats and their associated protein 13) is an emerging gene therapy approach for treating genetic disorders, but its therapeutic potential in genetic cardiomyopathy remains unexplored...
May 16, 2024: Circulation
https://read.qxmd.com/read/38743808/stepping-into-the-future-of-care-for-patients-with-pad
#6
JOURNAL ARTICLE
Marc P Bonaca, Naomi M Hamburg, Mark A Creager
No abstract text is available yet for this article.
May 14, 2024: Circulation
https://read.qxmd.com/read/38743805/2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity-peripheral-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-joint-committee-on-clinical-practice-guidelines
#7
REVIEW
Heather L Gornik, Herbert D Aronow, Philip P Goodney, Shipra Arya, Luke Packard Brewster, Lori Byrd, Venita Chandra, Douglas E Drachman, Jennifer M Eaves, Jonathan K Ehrman, John N Evans, Thomas S D Getchius, J Antonio Gutiérrez, Beau M Hawkins, Connie N Hess, Karen J Ho, W Schuyler Jones, Esther S H Kim, Scott Kinlay, Lee Kirksey, Debra Kohlman-Trigoboff, Chandler A Long, Amy West Pollak, Saher S Sabri, Lawrence B Sadwin, Eric A Secemsky, Maya Serhal, Mehdi H Shishehbor, Diane Treat-Jacobson, Luke R Wilkins
AIM: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia). METHODS: A comprehensive literature search was conducted from October 2020 to June 2022, encompassing studies, reviews, and other evidence conducted on human subjects that was published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline...
May 14, 2024: Circulation
https://read.qxmd.com/read/38742915/effect-of-cangrelor-on-infarct-size-in-st-segment-elevation-myocardial-infarction-treated-by-primary-percutaneous-coronary-intervention-a-randomized-controlled-trial-the-pitri-trial
#8
JOURNAL ARTICLE
Heerajnarain Bulluck, Jun Hua Chong, Jennifer Bryant, Annitha Annathurai, Ping Chai, Mervyn Chan, Ashish Chawla, Chee Yang Chin, Yiu-Cho Chung, Fei Gao, Hee Hwa Ho, Andrew Fu Wah Ho, John Hoe, Syed Saqib Imran, Chi-Hang Lee, Benji Lim, Soo Teik Lim, Swee Han Lim, Boon Wah Liew, Patrick Lim Zhan Yun, Marcus Eng Hock Ong, Valeria Paradies, Xuan Ming Pung, Julian Cheong Kiat Tay, Lynette Teo, Boon Ping Ting, Aaron Wong, Evelyn Wong, Timothy Watson, Mark Y Chan, Yeo Khung Keong, Jack W C Tan, Derek J Hausenloy
Background: The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarct (MI) size in the pre-clinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction (MVO) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: This was a Phase 2, multi-center, randomized, double-blind, placebo controlled clinical trial conducted between November 2017 to November 2021 in six cardiac centers in Singapore (NCT03102723)...
May 14, 2024: Circulation
https://read.qxmd.com/read/38742491/influence-of-pathophysiological-patterns-of-coronary-artery-disease-on-immediate-percutaneous-coronary-intervention-outcomes
#9
JOURNAL ARTICLE
Carlos Collet, Daniel Munhoz, Takuya Mizukami, Jeroen Sonck, Hitoshi Matsuo, Toshiro Shinke, Hirohiko Ando, Brian Ko, Simone Biscaglia, Fernando Rivero, Thomas Engstrøm, Ketina Arslani, Antonio Maria Leone, Lokien X van Nunen, William F Fearon, Evald Høj Christiansen, Stephane Fournier, Liyew Desta, Andy Yong, Julien Adjej, Javier Escaned, Masafumi Nakayama, Ashkan Eftekhari, Frederik M Zimmermann, Koshiro Sakai, Tatyana Storozhenko, Bruno R da Costa, Gianluca Campo, Nick E J West, Tom De Potter, Ward Heggermont, Dimitri Buytaert, Jozef Bartunek, Colin Berry, Damien Collison, Thomas Johnson, Tetsuya Amano, Divaka Perera, Allen Jeremias, Ziad Ali, Nico H J Pijls, Bernard De Bruyne, Nils P Johnson
BACKGROUND: Diffuse coronary artery disease (CAD) impacts the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiological CAD patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularisation and procedural outcomes. METHODS: This prospective, investigator-initiated, single-arm, multicentre study enrolled patients with at least one epicardial lesion with an FFR ≤ 0...
May 14, 2024: Circulation
https://read.qxmd.com/read/38733252/redefining-iron-deficiency-in-patients-with-chronic-heart-failure
#10
REVIEW
Milton Packer, Stefan D Anker, Javed Butler, John G F Cleland, Paul R Kalra, Robert J Mentz, Piotr Ponikowski, Khawaja M Talha
No abstract text is available yet for this article.
May 11, 2024: Circulation
https://read.qxmd.com/read/38733145/timing-of-cardio-kidney-protection-with-sglt2-inhibitors-insights-from-four-large-scale-placebo-controlled-outcome-trials
#11
LETTER
Brendon L Neuen, Brian L Claggett, Vlado Perkovic, Meg Jardine, Hiddo J L Heerspink, Kenneth W Mahaffey, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan
No abstract text is available yet for this article.
May 11, 2024: Circulation
https://read.qxmd.com/read/38726666/spexin-diminishes-atrial-fibrillation-vulnerability-by-acting-on-galanin-receptor-2
#12
JOURNAL ARTICLE
Desheng Li, Yang Liu, Changzhu Li, Zhiwen Zhou, Kangyi Gao, Hairong Ba, Jiming Yang, Genlong Xue, Dechun Yin, Xinbo Zhao, Kewei Shen, Lingmin Zhang, Jialiang Li, Chenhong Li, Jiahui Song, Lexin Zhao, Yao Pei, Lina Xuan, Yang Zhang, Yanjie Lu, Zhi-Ren Zhang, Baofeng Yang, Yue Li, Zhenwei Pan
BACKGROUND: G protein-coupled receptors play a critical role in atrial fibrillation (AF). Spexin is a novel ligand of galanin receptors (GALRs). In this study, we investigated the regulation of spexin and GALRs on AF and the underlying mechanisms. METHODS: Global spexin knockout (SPX-KO) and cardiomyocyte-specific GALRs knockout (GALR-cKO) mice underwent burst pacing electrical stimulation. Optical mapping was used to determine atrial conduction velocity and action potential duration...
May 10, 2024: Circulation
https://read.qxmd.com/read/38718139/2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of-the-american-heart-association-american-college-of-cardiology-joint-committee-on-clinical-practice-guidelines
#13
REVIEW
Steve R Ommen, Carolyn Y Ho, Irfan M Asif, Seshadri Balaji, Michael A Burke, Sharlene M Day, Joseph A Dearani, Kelly C Epps, Lauren Evanovich, Victor A Ferrari, José A Joglar, Sadiya S Khan, Jeffrey J Kim, Michelle M Kittleson, Chayakrit Krittanawong, Matthew W Martinez, Seema Mital, Srihari S Naidu, Sara Saberi, Christopher Semsarian, Sabrina Times, Cynthia Burstein Waldman
AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline...
May 8, 2024: Circulation
https://read.qxmd.com/read/38708635/adducin-regulates-sarcomere-disassembly-during-cardiomyocyte-mitosis
#14
JOURNAL ARTICLE
Feng Xiao, Ngoc Uyen Nhi Nguyen, Ping Wang, Shujuan Li, Ching-Cheng Hsu, Suwannee Thet, Wataru Kimura, Xiang Luo, Nicholas T Lam, Ivan Menendez-Montes, Waleed Elhelaly, Alisson Campos Cardoso, Ana Helena Macedo Pereira, Rohit Singh, Sakthivel Sadayappan, Mohammed Kanchwala, Chao Xing, Feria A Ladha, J Travis Hinson, Roger J Hajjar, Joseph A Hill, Hesham A Sadek
BACKGROUND: Recent interest in understanding cardiomyocyte cell cycle has been driven by potential therapeutic applications in cardiomyopathy. However, despite recent advances, cardiomyocyte mitosis remains a poorly understood process. For example, it is unclear how sarcomeres are disassembled during mitosis to allow the abscission of daughter cardiomyocytes. METHODS: Here, we use a proteomics screen to identify adducin, an actin capping protein previously not studied in cardiomyocytes, as a regulator of sarcomere disassembly...
May 6, 2024: Circulation
https://read.qxmd.com/read/38708602/inhibition-of-hmbox1-promotes-cardiomyocyte-survival-and-glucose-metabolism-through-gck-activation-in-ischemia-reperfusion-injury
#15
JOURNAL ARTICLE
Yihua Bei, Yujiao Zhu, Jingwen Zhou, Songwei Ai, Jianhua Yao, Mingming Yin, Meiyu Hu, Weitong Qi, Michail Spanos, Lin Li, Meng Wei, Zhenzhen Huang, Juan Gao, Chang Liu, Petra H van der Kraak, Guoping Li, Zhiyong Lei, Joost P G Sluijter, Junjie Xiao
BACKGROUND: Exercise-induced physiological cardiac growth regulators may protect the heart from ischemia/reperfusion (I/R) injury. Homeobox-containing 1 (Hmbox1), a homeobox family member, has been identified as a putative transcriptional repressor and is downregulated in the exercised heart. However, its roles in exercise-induced physiological cardiac growth and its potential protective effects against cardiac I/R injury remain largely unexplored. METHODS: We studied the function of Hmbox1 in exercise-induced physiological cardiac growth in mice after 4 weeks of swimming exercise...
May 6, 2024: Circulation
https://read.qxmd.com/read/38695173/deficiency-of-the-deubiquitinase-uchl1-attenuates-pulmonary-arterial-hypertension
#16
JOURNAL ARTICLE
Haiyang Tang, Akash Gupta, Seth A Morrisroe, Changlei Bao, Tae-Hwi Schwantes-An, Geetanjali Gupta, Shuxin Liang, Yanan Sun, Aiai Chu, Ang Luo, Venkateswaran Ramamoorthi Elangovan, Shreya Sangam, Yinan Shi, Samisubbu R Naidu, Jia-Rong Jheng, Sultan Ciftci-Yilmaz, Noel A Warfel, Louise Hecker, Sumegha Mitra, Anna W Coleman, Katie A Lutz, Michael W Pauciulo, Yen-Chun Lai, Ali Javaheri, Rohan Dharmakumar, Wen-Hui Wu, Daniel P Flaherty, Jason H Karnes, Sandra Breuils-Bonnet, Olivier Boucherat, Sebastien Bonnet, Jason X-J Yuan, Jeffrey R Jacobson, Julio D Duarte, William C Nichols, Joe G N Garcia, Ankit A Desai
BACKGROUND: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), a deubiquitinase, has been shown to reduce AKT1 (AKT serine/threonine kinase 1) degradation, resulting in higher levels. Given that AKT1 is pathological in pulmonary hypertension, we hypothesized that UCHL1 deficiency attenuates PAH development by means of reductions in AKT1...
May 2, 2024: Circulation
https://read.qxmd.com/read/38690659/ertugliflozin-for-functional-mitral-regurgitation-associated-with-heart-failure-effort-trial
#17
JOURNAL ARTICLE
Duk-Hyun Kang, Sung-Ji Park, Sung-Hee Shin, In-Chang Hwang, Yeonyee Elizabeth Yoon, Hyung-Kwan Kim, Mijin Kim, Min-Seok Kim, Sung-Cheol Yun, Jong-Min Song, Seok-Min Kang
BACKGROUND: The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction. METHODS: The EFFORT trial (Ertugliflozin for Functional Mitral Regurgitation) was a multicenter, double-blind, randomized trial to examine the hypothesis that the sodium-glucose cotransporter 2 inhibitor ertugliflozin is effective for improving MR in patients with HF with New York Heart Association functional class II or III, 35%≤ejection fraction<50%, and effective regurgitant orifice area of chronic functional MR >0...
May 1, 2024: Circulation
https://read.qxmd.com/read/38686562/rectifying-mettl4-mediated-n-6-methyladenine-excess-in-mitochondrial-dna-alleviates-heart-failure
#18
JOURNAL ARTICLE
Fuyang Zhang, Ling Zhang, Guangyu Hu, Xiyao Chen, Hui Liu, Congye Li, Xiong Guo, Chong Huang, Fangfang Sun, Tongzheng Li, Zhe Cui, Yongzhen Guo, Wenjun Yan, Yunlong Xia, Zhiyuan Liu, Zhen Lin, Weixun Duan, Linhe Lu, Xinyi Wang, Zhengyang Wang, Shan Wang, Ling Tao
BACKGROUND: Myocardial mitochondrial dysfunction underpins the pathogenesis of heart failure (HF), yet therapeutic options to restore myocardial mitochondrial function are scarce. Epigenetic modifications of mitochondrial DNA (mtDNA), such as methylation, play a pivotal role in modulating mitochondrial homeostasis. However, their involvement in HF remains unclear. METHODS: Experimental HF models were established through continuous angiotensin II and phenylephrine (AngII/PE) infusion or prolonged myocardial ischemia/reperfusion injury...
April 30, 2024: Circulation
https://read.qxmd.com/read/38686559/atherosclerosis-is-a-smooth-muscle-cell-driven-tumor-like-disease
#19
JOURNAL ARTICLE
Huize Pan, Sebastian E Ho, Chenyi Xue, Jian Cui, Quinian S Johanson, Nadja Sachs, Leila S Ross, Fang Li, Robert A Solomon, E Sander Connolly, Virendra I Patel, Lars Maegdefessel, Hanrui Zhang, Muredach P Reilly
BACKGROUND: Atherosclerosis, a leading cause of cardiovascular disease, involves the pathological activation of various cell types, including immunocytes (eg, macrophages and T cells), smooth muscle cells (SMCs), and endothelial cells. Accumulating evidence suggests that transition of SMCs to other cell types, known as phenotypic switching, plays a central role in atherosclerosis development and complications. However, the characteristics of SMC-derived cells and the underlying mechanisms of SMC transition in disease pathogenesis remain poorly understood...
April 30, 2024: Circulation
https://read.qxmd.com/read/38682338/abcg2-expressing-clonal-repopulating-endothelial-cells-serve-to-form-and-maintain-blood-vessels
#20
JOURNAL ARTICLE
Yang Lin, Chang-Hyun Gil, Kimihiko Banno, Masataka Yokoyama, Matthew Wingo, Ellen Go, Nutan Prasain, Ying Liu, Takashi Hato, Hisamichi Naito, Taku Wakabayashi, Musia Sominskaia, Meng Gao, Kevin Chen, Fuqiang Geng, Jesus Maria Gomez Salinero, Sisi Chen, W Christopher Shelley, Momoko Yoshimoto, Sergio Li Calzi, Michael P Murphy, Kyoji Horie, Maria B Grant, Ryan Schreiner, David Redmond, David P Basile, Shahin Rafii, Mervin C Yoder
BACKGROUND: Most organs are maintained lifelong by resident stem/progenitor cells. During development and regeneration, lineage-specific stem/progenitor cells can contribute to the growth or maintenance of different organs, whereas fully differentiated mature cells have less regenerative potential. However, it is unclear whether vascular endothelial cells (ECs) are also replenished by stem/progenitor cells with EC-repopulating potential residing in blood vessels. It has been reported recently that some EC populations possess higher clonal proliferative potential and vessel-forming capacity compared with mature ECs...
April 29, 2024: Circulation
journal
journal
20069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.